Outcome of the Board Meeting held today on 12th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported standalone unaudited results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations rose to Rs. 3,552.68 lakhs from Rs. 3,253.57 lakhs in Q1 FY25, a growth of about 9.2% year-on-year. Total income stood at Rs. 3,758.39 lakhs. Profit after tax increased modestly to Rs. 779.18 lakhs (up ~5% YoY) with EPS of Rs. 17.66 versus Rs. 16.80 earlier. However, other expenses jumped sharply to Rs. 833.11 lakhs from Rs. 628.88 lakhs, and depreciation rose to Rs. 72.25 lakhs from Rs. 51.90 lakhs, which compressed operating margins. The auditor (D.R. Mehta & Associates) issued an unmodified limited review report with no qualifications.
Steady but slowing growth - revenue and PAT grew in single digits while costs rose faster, weighing on margins. The clean audit report is reassuring, but the margin compression may temper near-term investor enthusiasm.